|
|
|
front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |review |
 |
Ondansetron – anti-emetic; selective antagonist of a
specific type of serotonin receptor (5-HT3) located in the CNS – area
postrema (chemoreceptor trigger zone), and in peripheral NS on nerve terminals of the
n.vagus. Used for prevention of nausea and vomiting associated with emetogenic
chemotherapy. Another Eg. @ Brigham and Women’s Hospital, Boston, Mass. – prevention of ADE by 17% Costs for developing+implementing $1.9 mln. With maintenance $500,000/yr. Net savings - $5-10 mln./yr. |